Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urcosimod in Neuropathic Corneal Pain
NCT06637527Phase 2Terminated
- Sponsor
- OKYO Pharma Limited
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of urcosimod in neuropathic corneal pain (NCP), sponsored by OKYO Pharma Limited. Started Oct 2024; status: terminated.
02
Drugs
urcosimod
03
Conditions
neuropathic corneal pain (NCP)
Beyond the preview
Go deeper on NCT06637527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637527.